Article
Cell Biology
Xi Yang, Yuanfeng Wei, Feng Sheng, Yirong Xu, Jiao Liu, Ling Gao, Ju Yang, Xinchen Sun, Junxing Huang, Qing Guo
Summary: This study revealed that CXC chemokines are overexpressed in CRC tissues and correlated with tumor stage and clinical outcomes, as well as co-expression with EGFR, KRAS, and NRAS. Additionally, CXCL8/9/10/11 expression was significantly associated with immune infiltration in colonic and rectal adenocarcinoma.
Article
Oncology
Hiroya Taniguchi, Kentaro Yamazaki, Toshiki Masuishi, Takeshi Kawakami, Yusuke Onozawa, Kazunori Honda, Shigenori Kadowaki, Yukiya Narita, Takahiro Tsushima, Satoshi Hamauchi, Akiko Todaka, Tomoya Yokota, Masashi Ando, Keita Mori, Hiromichi Shirasu, Hirofumi Yasui, Kei Muro
Summary: In this phase Ib study, trifluridine/tipiracil, irinotecan, and bevacizumab were tested in patients with metastatic colorectal cancer. The treatment showed moderate antitumor activity but had a high risk of severe myelotoxicity.
Article
Oncology
G. Carlsson, A. Koumarianou, T. K. Guren, J. Haux, P. Katsaounis, N. Kentepozidis, P. Pfeiffer, M. Braendengen, D. Mavroudis, H. Taffin, L. Skintemo, R. Tell, C. Papadimitriou
Summary: Arfolitixorin, a new form of folate, has shown promise in improving the treatment outcomes of colorectal cancer. This study demonstrated that Arfolitixorin, when combined with 5-FU, is well-tolerated and can achieve partial response. Additionally, there were no significant pharmacokinetic differences observed. These findings suggest that Arfolitixorin could be a potential treatment option for patients with colorectal cancer.
Article
Oncology
Helene Bellio, Aurelie Bertaut, Alice Hervieu, Sylvie Zanetta, Audrey Hennequin, Julie Vincent, Remi Palmier, Leila Bengrine-Lefevre, Francois Ghiringhelli, Jean-David Fumet
Summary: The treatment of metastatic colorectal cancer involves combination therapies based on various drugs and targeted therapy, with the aim of evaluating safety, tolerance, and efficacy in chemorefractory patients. The study assessed a new regimen, FOLFIRINOX-3 bevacizumab, and found it to be well-tolerated with a high response rate in chemorefractory patients.
Article
Oncology
Reem D. Mahmood, Danielle Shaw, Tine Descamps, Cong Zhou, Robert D. Morgan, Saifee Mullamitha, Mark Saunders, Nerissa Mescallado, Alison Backen, Karen Morris, Ross A. Little, Susan Cheung, Yvonne Watson, James P. B. O'Connor, Alan Jackson, Geoff J. M. Parker, Caroline Dive, Gordon C. Jayson
Summary: Metastatic colorectal cancer patients receiving standard chemotherapy show changes in cell- and protein-based biomarkers, with no association to survival outcomes. However, an increase in the MRI imaging biomarker K-trans is associated with worse overall survival, indicating potential for directing molecularly targeted therapies.
Article
Mathematical & Computational Biology
Xiaoqi Sun, Qunxi Chen, Lihong Zhang, Jiewei Chen, Xinke Zhang
Summary: By analyzing data from various online tools and databases, it is found that the expression levels of CXC chemokines in BLCA tissues are closely associated with patient prognosis, linked to multiple signaling pathways and transcription factors, as well as specific immune cell infiltrations.
MATHEMATICAL BIOSCIENCES AND ENGINEERING
(2021)
Article
Oncology
Sadayuki Kawai, Nozomi Takeshima, Yu Hayasaka, Akifumi Notsu, Mutsumi Yamazaki, Takanori Kawabata, Kentaro Yamazaki, Keita Mori, Hirofumi Yasui
Summary: The study compared the efficacy and toxicity profiles of IRI- and Ox-based regimens as first-line treatments for mCRC, finding no significant difference in terms of overall survival, progression-free survival, and objective response rate between the two groups. However, there were differences in toxicity profile, with IRI-based regimens associated with higher incidence of certain adverse events, while Ox-based regimens had different toxicities such as thrombocytopenia and peripheral sensory neuropathy.
Article
Oncology
Fei Wang, Chong Yuan, He-Zhen Wu, Bo Liu, Yan-Fang Yang
Summary: This study used multiple databases and tools for analysis, and found that the expression of CXCL1-3, CXCL9-13 was significantly different between BC and normal tissues, and correlated with the stages of BC. Among them, CXCL1-3 were prone to mutation, negatively correlated with survival and prognosis of BC patients, and may serve as therapeutic targets and biomarkers for BC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Kentaro Masuhiro, Motohiro Tamiya, Kosuke Fujimoto, Shohei Koyama, Yujiro Naito, Akio Osa, Takashi Hirai, Hidekazu Suzuki, Norio Okamoto, Takayuki Shiroyama, Kazumi Nishino, Yuichi Adachi, Takuro Nii, Yumi Kinugasa-Katayama, Akiko Kajihara, Takayoshi Morita, Seiya Imoto, Satoshi Uematsu, Takuma Irie, Daisuke Okuzaki, Taiki Aoshi, Yoshito Takeda, Toru Kumagai, Tomonori Hirashima, Atsushi Kumanogoh
Summary: Bronchoalveolar lavage analysis can help predict the efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. Patients with higher levels of CXCL9 in BALF, greater diversity of lung microbiome profile in BALF, and higher frequency of CD56+ subset in blood T cells are more likely to respond to immune checkpoint inhibitors.
Article
Multidisciplinary Sciences
Yeong Hak Bang, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, Yong Sang Hong
Summary: The study evaluated the efficacy of bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer, finding that this combination showed significant disease control rates and survival outcomes in patients who had progressed with prior standard treatments.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Leonard B. Saltz, Stephen Clarke, Eduardo Diaz-Rubio, Werner Scheithauer, Arie Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai-Shen Yang, Fernando Rivera, Felix Couture, Florin Sirzen, Jim Cassidy
Summary: The purpose of this study was to evaluate the efficacy and safety of adding bevacizumab to first-line oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. The results showed that adding bevacizumab significantly improved progression-free survival, but had no significant effect on overall survival and response rate.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Vincenzo Nasca, Francesco Barretta, Francesca Corti, Sara Lonardi, Monica Niger, Maria Elena Elez, Marwan Fakih, Priya Jayachandran, Aakash Tushar Shah, Massimiliano Salati, Elisabetta Fenocchio, Lisa Salvatore, Chiara Cremolini, Javier Ros, Margherita Ambrosini, Giacomo Mazzoli, Rossana Intini, Michael J. Overman, Rosalba Miceli, Filippo Pietrantonio
Summary: In this study of 331 patients with metastatic colorectal cancer treated with immune checkpoint inhibitors, it was found that certain immune-related adverse events (irAEs) could affect patient survival, with some having a protective effect and others having a harmful effect. The study proposed a simple model to evaluate the impact of irAEs on treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Giovanni Fuca, Francesca Corti, Margherita Ambrosini, Rossana Intini, Massimiliano Salati, Elisabetta Fenocchio, Paolo Manca, Chiara Manai, Francesca Daniel, Alessandra Raimondi, Federica Morano, Salvatore Corallo, Michele Prisciandaro, Andrea Spallanzani, Virginia Quara, Carmen Belli, Marta Vaiani, Giuseppe Curigliano, Chiara Cremolini, Filippo De Braud, Maria Di Bartolomeo, Vittorina Zagonel, Sara Lonardi, Filippo Pietrantonio
Summary: This study found that early tumor shrinkage (ETS) and depth of response (DoR) were significantly associated with survival outcomes in patients with MSI-H/dMMR mCRC treated with immune checkpoint inhibitors (ICIs), suggesting that they may serve as important prognostic factors for designing treatment strategies. Prospective validation of these findings is recommended.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Medicine, Research & Experimental
Elham Fakhr, Fatemeh Zare, Kayhan Azadmanesh, Ladan Teimoori-Toolabi
Summary: LEF1 plays an important role in the chemo-resistance of colorectal cancer cells, with downregulation of the long isoform making cells more sensitive to chemotherapy through reduced proliferation, increased apoptosis, or cell cycle arrest. Balancing the expression of long and short isoforms of LEF1 is crucial in overcoming chemo-resistance.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Jiacheng Huang, Zhitao Chen, Chenchen Ding, Shengzhang Lin, Dalong Wan, Kuiwu Ren
Summary: The study revealed that the expression levels of CXC chemokines are significantly elevated in pancreatic cancer, with CXCL16 showing the highest expression. All CXC chemokines are associated with tumor-immune dysfunction, and the expression of certain chemokines is significantly linked to clinical outcomes in patients. Moreover, high expression of certain chemokines is related to unfavorable overall survival, with only one chemokine being associated with disease-free survival.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Eva Martinez-Balibrea, Anna Martinez-Cardus, Alba Gines, Vicenc Ruiz de Porras, Catia Moutinho, Laura Layos, Jose Luis Manzano, Cristina Buges, Sara Bystrup, Manel Esteller, Albert Abad
MOLECULAR CANCER THERAPEUTICS
(2015)
Article
Biochemistry & Molecular Biology
Belen Mezquita, Estela Pineda, Jovita Mezquita, Pau Mezquita, Montserrat Pau, Jordi Codony-Servat, Eva Martinez-Balibrea, Conchi Mora, Joan Maurel, Cristobal Mezquita
MOLECULAR CARCINOGENESIS
(2016)
Article
Oncology
Ming Yin, Jingrong Yan, Eva Martinez-Balibrea, Francesco Graziano, Heinz-Josef Lenz, Hyo-Jin Kim, Jacques Robert, Seock-Ah Im, Wei-Shu Wang, Marie-Christine Etienne-Grimaldi, Qingyi Wei
CLINICAL CANCER RESEARCH
(2011)
Article
Oncology
Dan Rosmarin, Claire Palles, David Church, Enric Domingo, Angela Jones, Elaine Johnstone, Haitao Wang, Sharon Love, Patrick Julier, Claire Scudder, George Nicholson, Anna Gonzalez-Neira, Miguel Martin, Daniel Sargent, Erin Green, Howard McLeod, Ulrich M. Zanger, Matthias Schwab, Michael Braun, Matthew Seymour, Lindsay Thompson, Benjamin Lacas, Valerie Boige, Nuria Ribelles, Shoaib Afzal, Henrik Enghusen, Soren Astrup Jensen, Marie-Christine Etienne-Grimaldi, Gerard Milano, Mia Wadelius, Bengt Glimelius, Hans Garmo, Milena Gusella, Thierry Lecomte, Pierre Laurent-Puig, Eva Martinez-Balibrea, Rohini Sharma, Jesus Garcia-Foncillas, Zdenek Kleibl, Alain Morel, Jean-Pierre Pignon, Rachel Midgley, David Kerr, Ian Tomlinson
JOURNAL OF CLINICAL ONCOLOGY
(2014)
Article
Oncology
Catia Moutinho, Anna Martinez-Cardus, Cristina Santos, Valentin Navarro-Perez, Eva Martinez-Balibrea, Eva Musulen, F. Javier Carmona, Andrea Sartore-Bianchi, Andrea Cassingena, Salvatore Siena, Elena Elez, Josep Tabernero, Ramon Salazar, Albert Abad, Manel Esteller
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2014)
Article
Oncology
Jordi Codony-Servat, Xabier Garcia-Albeniz, Carles Pericay, Vicente Alonso, Pilar Escudero, Carlos Fernandez-Martos, Rosa Gallego, Anna Martinez-Cardus, Eva Martinez-Balibrea, Joan Maurel
Article
Genetics & Heredity
M. M. Dias, J-P Pignon, C. S. Karapetis, V. Boige, B. Glimeliuss, D. M. Kweekel, P. N. Lara, P. Laurent-Puig, E. Martinez-Balibrea, D. Paez, C. J. A. Punt, M. W. Redman, G. Toffoli, M. Wadelius, R. A. McKinnon, M. J. Sorich
PHARMACOGENOMICS JOURNAL
(2014)
Article
Multidisciplinary Sciences
Alba Gines, Sara Bystrup, Vicenc Ruiz de Porras, Cristina Guardia, Eva Musulen, Anna Martinez-Cardus, Jose Luis Manzano, Laura Layos, Albert Abad, Eva Martinez-Balibrea
Article
Multidisciplinary Sciences
Paula Lopez-Serra, Miguel Marcilla, Alberto Villanueva, Antonio Ramos-Fernandez, Anna Palau, Lucia Leal, Jessica E. Wahi, Fernando Setien-Baranda, Karolina Szczesna, Catia Moutinho, Anna Martinez-Cardus, Holger Heyn, Juan Sandoval, Sara Puertas, August Vidal, Xavier Sanjuan, Eva Martinez-Balibrea, Francesc Vinals, Jose C. Perales, Jesper B. Bramsem, Torben F. Orntoft, Claus L. Andersen, Josep Tabernero, Ultan McDermott, Matthew B. Boxer, Matthew G. Vander Heiden, Juan Pablo Albar, Manel Esteller
NATURE COMMUNICATIONS
(2014)
Review
Biochemistry & Molecular Biology
Margarita Romeo, Juan Carlos Pardo, Anna Martinez-Cardus, Eva Martinez-Balibrea, Vanesa Quiroga, Sergio Martinez-Roman, Francesc Sole, Mireia Margeli, Ricard Mesia
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2018)
Article
Oncology
Vicenc Ruiz de Porras, Sara Bystrup, Sara Cabrero-de las Heras, Eva Musulen, Luis Palomero, Maria Henar Alonso, Rocio Nieto, Diego Arango, Victor Moreno, Cristina Queralt, Jose Luis Manzano, Laura Layos, Cristina Buges, Eva Martinez-Balibrea
Review
Biochemistry & Molecular Biology
Marta Domenech, Ainhoa Hernandez, Andrea Plaja, Eva Martinez-Balibrea, Carmen Balana
Summary: Glioblastoma is the most aggressive form of brain tumor in adults, with hypoxia-induced factor 1 (HIF-1) serving as an important driver of tumor progression by promoting angiogenesis, immunosuppression, and metabolic reprogramming. HIF-1 is not only regulated by oxygen levels but also by various oncogenic signaling pathways, and inhibiting the hypoxia pathway could be a crucial treatment alternative for GB patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Laura Layos, Eva Martinez-Balibrea, Vicenc Ruiz de Porras
Summary: Colorectal cancer is a common cancer in both men and women. Chemotherapy-induced toxicity and resistance are major obstacles in cancer treatment, but curcumin has been shown to have anti-cancer properties and the ability to alleviate side effects and overcome resistance. Therefore, adding curcumin to the standard chemotherapy treatment for metastatic colorectal cancer could improve patient quality of life.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
A. Abad, E. Martinez-Balibrea, J. Ma Vieitez, V. Alonso-Orduna, P. Garcia Alfonso, J. L. Manzano, B. Massuti, M. Benavides, A. Carrato, M. Zanui, J. Gallego, C. Gravalos, V. Conde, M. Provencio, M. Valladares-Ayerbes, R. Salazar, J. Sastre, C. Montagut, F. Rivera, E. Aranda
ANNALS OF ONCOLOGY
(2018)